Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
SAN DIEGO --(BUSINESS WIRE)--Apr. 14, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020 , it has now received more than 350,000 samples for testing.
View HTML
Toggle Summary Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University W ebinar begins tomorrow, April 8 , at 12:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 7, 2021-- Biocept, Inc.
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees.
View HTML
Toggle Summary Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products
View HTML
Toggle Summary Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
Q4 features revenues of $18.5 million ; 2020 revenues reach $27.5 million driven by COVID-19 testing Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system Conference call begins at 4:30 p.m.
View HTML
Toggle Summary Biocept to Report 2020 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 29, 2021
SAN DIEGO --(BUSINESS WIRE)--Mar. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 months ended December 31, 2020 after the market closes on Monday, March 29, 2021
View HTML
Toggle Summary Biocept to Participate in Three Virtual Investment Conferences in March
Company presentation features neuro-oncology program with goal of becoming standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the central nervous system (CNS) Provides update on COVID-19 testing with more than 300,000 samples received SAN DIEGO
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Mar. 3, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees.
View HTML
Toggle Summary Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
COVID-19 test, based on Aegea’s next-generation COVID-19 assay kit using Switch-Blocker™ technology, may provide answers that support screening and managing patients SAN DIEGO --(BUSINESS WIRE)--Mar. 2, 2021-- Aegea Biotechnologies, Inc. , an innovative life science company with an extensive
View HTML
Toggle Summary Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients
Target Selector™ EGFR assays offer ultra-high sensitivity and require less tumor sample than most commercial assays SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean
View HTML